Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vivalis has signed a research license with an animal health company to evaluate EBx cell line for the production of several viral vaccines.
Subscribe to our email newsletter
Franck Grimaud, CEO of Vivalis, said: “This new license confirms again that the EBx cell platform is a reference cell substrate for the industrial manufacture of viral vaccines.
“We are strongly convinced that an increasing number of vaccine companies will move away from chicken eggs and adopt the EBx cell platform as their standard production platform in a foreseeable future.”